Innovative two-step negative selection of granulocyte colony-stimulating factor-mobilized circulating progenitor cells: Adequacy for autologous and allogeneic transplantation

Blood

Volumn 91, Issue 6, 1998, Pages 2189-2196

  Rambaldi, Alessandro ^a   Borleri, Gianmaria ^b   Dotti, Gianpietro ^b   Bellavita, Piermario ^b   Amaru, Ricardo ^b   Biondi, Andrea ^b   Barbui, Tiziano ^b  

^a OSPEDALI RIUNITI   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CD11B ANTIGEN; CD19 ANTIGEN; CD3 ANTIGEN; CD34 ANTIGEN; CD6 ANTIGEN; CHROMIUM CHLORIDE; CYTOKINE ANTIBODY; GRANULOCYTE COLONY STIMULATING FACTOR; LEUKOCYTE ANTIGEN; MONOCLONAL ANTIBODY;

ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; B CELL LYMPHOMA; CONTROLLED STUDY; DENSITY GRADIENT CENTRIFUGATION; ERYTHROCYTE; HEMATOPOIETIC STEM CELL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUMAN CELL; LEUKAPHERESIS; LYMPHOCYTE DEPLETION; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; T CELL LEUKEMIA;

EID: 0032521475     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v91.6.2189     Document Type: Article

References (43)

1. Krause DS, Fackler MJ, Civin CI, May S: CD34: Structure, biology, and clinical utility. Blood 87:1, 1996
2. To LB, Haylock DN, Simmons PJ, Juttner CA: The biology and clinical use of blood stem cells. Blood 89:2233, 1997
3. Lowemberg B, Voogt P: Autologous stem cell transplantation and purging. J Clin Oncol 14:2194, 1996
4. + blood cells. Blood 87:4903, 1996
5. Dilloo D, Rill D, Entwistle C, Boursnell M, Zhong W, Holden W, Hommaday M, Inglis S, Brenner M: A novel Herpes vector for the high-efficiency transduction of normal and malignant human hematopoietic cells. Blood 89:119, 1997
6. + cells. Blood 84:1408, 1994
7. Shpall EJ, Jones RB: Release of tumors cells from bone marrow. Blood 83:623, 1994
8. Brugger W, Bross KJ, Glatt M, Weber F, Mertelsmann R, Kanz L: Mobilization of tumors cells and hematopoietic progenitor cells into peripheral blood of patients with solid tumors. Blood 83:636, 1994
9. + cells to remove circulating tumors cells. Blood 87:1625, 1996
10. Rill DR, Santana VM, Roberts WM, Nilson T, Bowman LC, Krance RA, Heslop HE, Moen RC, Ihle JN, Brenner MK: Direct demonstration that autologous bone marrow transplantation for solid tumors can return a multiplicity of tumorigenic cells. Blood 84:380, 1994
11. + bone marrow progenitor cells in patients with non-Hodgkin's lymphoma. Blood 85:1647, 1995
12. Shpall EJ, Janes RB, Bearman SJ, Franklin WA, Archer PG, Curiel T, Bitter M, Claman HN, Stemmer SM, Purdy M, Myers SE, Hami L, Taffs S, Heimfeld S, Hallagan J, Berenson RJ: Transplantation of enriched CD34-positive autologous marrow into breast cancer patients following high-dose chemotherapy: Influence of CD34-positive pheripheral-blood progenitores and growth factors on engraftment. J Clin Oncol 12:28, 1994
13. + cells in patients with breast cancer or neuroblastoma. Blood 84:1241, 1994
14. Berger KM, Rapatel C, de Lumley L, Lutz P, Plantaz D, Vannier JP, Bergeron C, Mechinaud F, Favrot M, Bonhomme J, Travade P, Demeoco F: CD34+ cell immunoselection from G-CSF-alone-primed peripheral blood in children with low body mass. BrJ Haematol 91:431, 1995
15. Alcorn MJ, Holyoake TL, Richmond L, Pearson C, Farrel E, Kyle B, Dunlop DJ, Fitzsimons E, Steward WP, Pragnell IB, Franklin IM: CD34-positive cells isolated from cryopreserved pheripheral-blood progenitor cells can be expanded ex vivo and used for transplantation with little or no toxicity. J Clin Oncol 14:1839, 1996
16. + pheripheral blood stem cells in patients with advanced hematologic malignancy. Blood 88:4132, 1996
17. + selected cells from peripheral blood. Blood 89:3967, 1997
18. Delain M, Cahn JY, Racadot E, Flesch M, Plouvier E, Mercier M, Tiberghien P, Pavy JJ, Deschaseaux M, Deconinck E, Couteret Y, Brion A, Herve P: Graft failure after T cell depleted HLA identical allogeneic bone marrow transplantation: Risk factors in leukemic patients. Leuk Lymphoma 11:359, 1993
19. Cortelazzo S, Viero P, Bellavita P, Rossi A, Buelli M, Borleri GM, Marchioli S, Bassan R, Comotti B, Rambaldi A, Barbui T: Granulocyte colony stimulating factor following pheripheral blood progenitor cells transplant in non-Hodgkin's lymphoma. J Clin Oncol 13:935, 1995
20. Rambaldi A, Viero P, Bassan R, Buelli M, Rossi A, Bellavita P, Spinelli O, Amaru R, Micheletti M, Borleri G, Cortelazzo S, Comotti B, Barbui T: G-CSF-mobilized pheripheral blood progenitor cells for allogeneic transplantation of resistant or relapsing acute leukemias. Leukemia 10:860, 1995
21. Anderson KC, Griffin JD, Bates MP, Slaughenhoupt BL, Schlossman SF, Nadler LM: Isolation and characterization of human B lymphocyte enriched population. I. Purification of B cells by immune rosette depletion. J Immunol Methods 61:283, 1983
22. Van Camp B, Durie BGM, Spier C, De Waele M, Van Riet I, Vela E, Fruttiger Y, Richter L, Grogan TM: Plasma cells in multiple myeloma express a natural killer cell-associated antigen: CD56 (NKH-1 ; Leu-19). Blood 76:377, 1990
23. Biondi A, Rambaldi A: Polymerase chain reaction (PCR) approach for the evaluation of minimal residual disease in acute leukemia. Stem Cells 12:394, 1994
24. Steward CG, Potter MN, Oakhill A: Third complementary determining region (CDRIII) sequence analysis in childhood B-lineage acute lymphoblastic leukemia: Implication for the design of oligonucleotide probes for use in monitoring minimal residual disease. Leukemia 6:1213, 1992
25. Gribben JG, Saporito L, Barber M, Blake KW, Edwards RM, Griffin JD, Freedman AS, Nadler LM: Bone marrow of non-Hodgkin's lymphoma patients with a bcl-2 translocation can be purged of ploymerase chain reaction-detecable lymphoma cells using monoclonal antibodies and immunomagnetic beads depletion. Blood 80:1083, 1992
26. + peripheral blood cells expressing CD38, CD56 and monotypic Ig light chain. Blood 85:436, 1995
27. Szczepek AJ, Bergsagel PL, Axelsson L, Brown CB, Belch AR, Pilarski LM: CD34+ cells in the blood of patients with multiple myeloma express CD19 and IgH mRNA and have patients-specific IgH VDJ gene rearrangements. Blood 89:1824, 1997
28. Majolino I, Saglio G, Scimé R, Serra A, Cavallaro AM, Fiandaca T, Vasta S, Pampinella M, Catania P, Indovina A, Marcenò R, Santoro A: High incidence of chronic GVHD after primary allogeneic peripheral blood stem cells transplantation in patients with hematologic malignancies. Bone Marrow Transplant 17:555, 1996
29. Marmont A, Horowitz MM, Gale RP, Sobocinski K, Ash RC, Bekkum DW, Champlin RE, Dicke KA, Goldman RA, Herzing RH, Hong R, Masaoka T, Rimm AA, Ringden O, Speck B, Weiner RS, Bortin MM: T-cell depletion of HLA identical transplant in leukemia. Blood 78:2120, 1991
30. Verdonck LF, Dekker AW, de Gast GC, van Kempen ML, Lokhorst HM, Nieuwenhuis HK: Allogeneic bone marrow transplantation with a fixed low number of T cells in the marrow graft. Blood 83:3090, 1994
31. Storb R, Deeg HJ, Whithead J, Appelbaum F, Beatty P, Bensinger WI, Buckner CD, Clift R, Doney K, Farewell V, Hansen J, Hill R, Lum R, Martin P, McGuffin R, Sanders J, Stewart P, Sullivan K, Witherspoon R, Yee J, Thomas ED: Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute-graft-versus-host disease after marrow transplantation for leukemia. N Engl J Med 314:729, 1986
32. Dunbar CE, Cottler-Fox M, O'Shaunessy JA, Doren S, Carter C, Berenson R, Brown S, Moen RC, Greenblatt J, Stewart FM, Leitman SF, Wilson VH, Cowan K, Young NS, Nienhuis AW: Retrovirally marked CD34-enriched peripheral blood and marrow cells contribute to long-term engraftment after autologous transplantation. Blood 85:3048, 1995
33. Willems P, Croockewit R, Raymarkers R, Holdrinet G, van der Bosh G, Huys E, Mesink E: CD34+ selection from myeloma peripheral blood cell autografts contain residual tumor cells due to impurity, not to CD34+ myeloma cells. Br J Haematol 93:613, 1996
34. + progenitors in bone marrow of BCL2-IgH-positive follicular lymphoma patients. Blood 86:4691, 1995
35. Mapara MY, Korner IJ, Hildebranndt M, Bargou R, Krahl D, Reichardt P, Dorken B: Monitoring of tumor cell purging after highly efficient immunomagnetic selection of CD34 cell from leukapheresis products in breast cancer patients: Comparison of immunocytochemical tumor cell staining and reverse transcriptase-polimerace chain reaction. Blood 89:337, 1997
36. Anderson KC, Ritz J, Takvorian T, Coral F, Daley H, Gorgone BC, Freedman AS, Canellos GP, Schlossman SF, Nadler LM: Hematologic engraftment and immune reconstitution posttransplantation with anti-B1 purged autologous bone marrow. Blood 69:597, 1987
37. Uckun FM, Reaman GH: Immunotoxins for treatment of leukemia and lymphoma. Leuk Lymphoma 18:195, 1995
38. Di Nicola M, Siena S, Corradini P, Bregni M, Milanesi M, Magni M, Ruffini PA, Ravagnani F, Tarella C, Gianni AM: Elimination of bcl-2-positive follicular lymphoma cells from blood transplants with high recovery of haematopoietic progenitors by the Miltenyi CD34+ cell sorting system. Bone Marrow Transplant 18:1117, 1996
39. Bertolini F, Thomas T, Battaglia M, Gibelli N, Pedrazzoli P, Robustelli della Cuna G: A new two-step procedure for 4.5 log depletion of T and B cells in allogeneic transplantation and of neoplastic cells in autologous transplantation. Bone Marrow Transplant 19:615, 1997
40. Soiffer RJ, Roy DC, Gonin R, Murray C, Anderson KC, Freedman AS, Babinowe SAN, Roberts MJ, Spector N, Pesek K, Mauch P, Nadler LM, Ritz J: Monoclonal antibody-purged autologous bone marrow transplatation in adults with acute lymphoblastic leukemia at high risk of relapse. Bone Marrow Transplant 12:243, 1993
41. Gribben JG, Freedman AS, Neuberg D, Roy DC, Blake KW, Woo SD, Grossbard ML, Rabinowe SN, Coral F, Freeman GJ, Ritz J, Nadler LM: Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma. N Engl J Med 325:1525, 1991
42. Brenner MK, Rill DR, Moen RC, Krance RA, Mirro J, Anderson WF, Ihle JN: Gene-marking to trace origin of relapse after autologous bone-marrow transplantation. Lancet 341:85, 1993
43. +Cells present in autologous transplants of chronic myelogenous leukemias (CML) contribute to relapse after autologous bone marrow in CML. Blood 83:3068, 1994